Additionally, a sizeable subgroup of MM patients will acquire de novo first hits to TP53, and/or progresses from single-hit to double-hit constellations during the course of their disease under treatment, thus in effect genetically switching into a class with high-risk features11–13,22,23. The gene discussed is TP53; the disease is Miyoshi myopathy.